Skip to main content
SpringerLink
Log in

Parathyroid Carcinoma

  • Chapter
  • First Online:
Medical and Surgical Treatment of Parathyroid Diseases

  • 1017 Accesses

Abstract

Parathyroid cancer is a rare cause of hyperparathyroidism and an even rarer malignancy. It continues to be very difficult to diagnosis preoperatively despite clues such as abnormally high PTH, symptomatic hypercalcemia, and at times a neck mass. Over the last decade we have substantially increased our understanding of the pathophysiology of the disease thanks to recognition of the HRPT2 mutation in hyperparathyroidism-jaw tumor syndrome which codes for parafibromin, a key protein involved in multiple cellular pathways for proliferation. This has substantially improved our ability to make the pathologic diagnosis and offers some promise of targeted therapies. This chapter will review the classic and most current literature on the epidemiology, presentation, diagnosis, and treatment of the disease including the latest developments in immunohistochemistry, imaging, staging, medical management of severe hypercalcemia, surgical treatment, and radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ruda JM, Hollenbeak CS, Stack Jr BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359–72. Clinical Review: Level 3, Grade B.

    Article  PubMed  Google Scholar 

  2. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973;31. Population/Observational Study: Level 3, Grade A.

    Google Scholar 

  3. Koea JB, Shaw JH. Parathyroid cancer: biology and management. Surg Oncol. 1999;8:155–65. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base report. Cancer. 1999;86:538–44. Population/Observational Study: Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  5. Al-Kurd A, Mekel M, Mazeh H. Parathyroid carcinoma. Surg Oncol. 2014;23:107–14. doi:10.1016/j.suronc.2014.03.005. Clinical review: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  6. Owen RP, Silver CE, Pellitteri PK, Shaha AR, Devaney KO, Werner JA, et al. Parathyroid carcinoma: a review. Head Neck. 2011;33:429–36. doi:10.1002/hed.21376. Clinical Review: Level 3, Grade A.

    PubMed  Google Scholar 

  7. Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13:11–23. Clinical review: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  8. Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992;71:197–205. Population/Observational Study: Level 4.

    Article  CAS  Google Scholar 

  9. Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16:724–31. Population/Observational Study: Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  10. Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol. 1993;17:820–9. Population/Observational Study: Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  11. DeLellis R, Lloyd R, Heitz P, Eng C, editors. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. Clinical review: Level 3, Grade A.

    Google Scholar 

  12. Ippolito G, Palazzo FF, Sebag F, De Micco C, Henry JF. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94:566–70. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  13. Gill AJ. Understanding the genetic basis of parathyroid carcinoma. Endocr Pathol. 2014;25:30–4. doi:10.1007/s12022-013-9294-3. Basic Science Review: Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  14. Kruijff S, Sidhu SB, Sywak MS, Gill AJ, Delbridge LW. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2014;21:426–33. doi:10.1245/s10434-013-3288-8. Clinical Investigation: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  15. Juhlin CC, Höög A. Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse? Int J Endocrinol. 2010:324964. doi: 10.1155/2010/324964. Basic Science Review: Level 1; Grade A.

  16. Ohkuwa K, Masaki C, Akaishi J, Suzuki A, Uruno T, Shibuya H, et al. Association between expression of Ki-67, parafibromin, p27, and Rb protein and the biological behavior in parathyroid tumors. Presented at the 15th European Congress of Endocrinology ECE 2013, Copenhagen, Denmark. Endocrine Abstracts. 2013;32:536. doi: 10.1530/endoabs.32.P536. Basic Science: Level 1, Grade B.

  17. Gene, ID: 79577. National Center for Biotechnology Information, Bethesda. 2015. http://www.ncbi.nlm.nih.gov/gene/79577. Accessed 26 Sept 2015. Basic Science: Level 1; Grade A.

  18. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629–37. Basic Science: Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  19. Gene, ID: 1027. National Center for Biotechnology Information, Bethesda. 2015. http://www.ncbi.nlm.nih.gov/gene/1027. Accessed 26 Sept 2015. Basic Science: Level 1; Grade A.

  20. Gene, ID: 7345. National Center for Biotechnology Information, Bethesda. 2015. http://www.ncbi.nlm.nih.gov/gene/7345. Accessed 26 Sept 2015.Basic Science: Level 1; Grade A.

  21. Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab. 2009;94:434–41. doi:10.1210/jc.2008-1740. Basic Science: Level 1; Grade B.

    Article  CAS  PubMed  Google Scholar 

  22. Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol. 2005;36:908–14. Basic Science: Level 1; Grade B.

    Article  CAS  PubMed  Google Scholar 

  23. Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Bränström R, et al. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol. 2009;34:481–92. Basic Science: Level 1; Grade B.

    CAS  PubMed  Google Scholar 

  24. Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol. 2010;21:166–77. doi:10.1007/s12022-010-9121-z. Basic Science: Level 1; Grade B.

    Article  CAS  PubMed  Google Scholar 

  25. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  26. Chow E, Tsang RW, Brierley JD, Filice S. Parathyroid carcinoma-the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1998;41:569–72. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  27. Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–85. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  28. Erovic BM, Goldstein DP, Kim D, Mete O, Brierley J, Tsang R, et al. Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck. 2013;35:35–9. doi:10.1002/hed.22908. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  29. Wilkins BJ, Lewis Jr JS. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol. 2009;3:140–9. Clinical review: Level 4.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  31. Schaapveld M, Jorna FH, Aben KK, Haak HR, Plukker JT, Links TP. Incidence and prognosis of parathyroid gland carcinoma: a population-based study in The Netherlands estimating the preoperative diagnosis. Am J Surg. 2011;202:590–7. Population/Observational Study: Level 2, Grade B.

    Article  PubMed  Google Scholar 

  32. Neumann DR, Esselstyn Jr CB, MacIntyre WJ, Chen EQ, Go RT, Licata AA. Regional body FDG-PET in postoperative recurrent hyperparathyroidism. J Comput Assist Tomogr. 1997;21:25–8. Clinical Investigation: Level 2, Grade B.

    Article  CAS  PubMed  Google Scholar 

  33. Evangelista L, Sorgato N, Torresan F, Boschin IM, Pennelli G, Saladini G, et al. FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol. 2011;2:348–54. doi:10.5306/wjco.v2.i10.348. Clinical Review: Level 4.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Alabed YZ, Rakheja R, Novales-Diaz JA, Lisbona R. Recurrent parathyroid carcinoma appearing as FDG negative but MIBI positive. Clin Nucl Med. 2014;39:e362–4. doi:10.1097/RLU.0000000000000357. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  35. Reeder SB, Desser TS, Weigel RJ, Jeffrey RB. Sonography in primary hyperparathyroidism: review with emphasis on scanning technique. J Ultrasound Med. 2002;21:539–52. Clinical Review: Level 4.

    PubMed  Google Scholar 

  36. Sidhu PS, Talat N, Patel P, Mulholland NJ, Schulte KM. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol. 2011;21:1865–73. Clinical Investigation: Level 4.

    Article  PubMed  Google Scholar 

  37. Tamler R, Lewis MS, LiVolsi VA, Genden EM. Parathyroid carcinoma: ultrasonographic and histologic features. Thyroid. 2005;15:744–5. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  38. Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86. doi:10.1210/jc.2011-1571. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  39. Agarwal G, Dhingra S, Mishra SK, Krishnani N. Implantation of parathyroid carcinoma along fine needle aspiration track. Langenbecks Arch Surg. 2006;391:623–6. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  40. Spinelli C, Bonadio AG, Berti P, Materazzi G, Miccoli P. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest. 2000;23:255–7. Clinical Investigation: Level 4.

    Article  CAS  PubMed  Google Scholar 

  41. Fernandez-Ranvier GG, Khanafshar E, Jensen K, Zarnegar R, Lee J, Kebebew E, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110:255–64. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  42. Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer. 1999;86:378e80. Clinical Review: Level 5.

    Article  Google Scholar 

  43. Schulte KM, Gill AJ, Barczynski M, Karakas E, Miyauchi A, Knoefel WT, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19:2620–8. doi:10.1245/s10434-012-2306-6. Population/Observational Study: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  44. Villar-del-Moral J, Jiménez-García A, Salvador-Egea P, Martos-Martínez JM, Nuño-Vázquez-Garza JM, Serradilla-Martín M, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156:1132–44. doi:10.1016/j.surg.2014.05.014. Population/Observational Study: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  45. Carpten JD, Robbins CM, Villablanca A. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676–80. Basic Science: Level 1; Grade B.

    Article  CAS  PubMed  Google Scholar 

  46. Shattuck T, Stiina V, Obara T, et al. Somatic and Germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722–9. Clinical Investigation: Level 2, Grade B.

    Article  CAS  PubMed  Google Scholar 

  47. Aguilera IM, Vaughan RS. Calcium and the anaesthetist. Anaesthesia. 2000;55:779–90. Clinical Review: Level 1; Grade A.

    Article  CAS  PubMed  Google Scholar 

  48. Maier JD, Levine SN. Hypercalcemia in the intensive care unit: a review of pathophysiology, diagnosis, and modern therapy. J Intensive Care Med. 2015;30:235–52. Clinical Review: Level 1, Grade A.

    Article  PubMed  Google Scholar 

  49. Shane E, Berenson JR. Treatment of hypercalcemia. 2015. http://www.uptodate.com. Accessed 6 July 2015. Clinical Review: Level 1, Grade A.

  50. LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med. 2008;149:259–63. Clinical Review: Level 1, Grade A.

    Article  PubMed  Google Scholar 

  51. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3803–8. Clinical Investigation: Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  52. Schwartz JJ, Rosenbaum SH. Anesthesia and the endocrine system. In: Barash PG, Cullen BF, Stoelting RK, editors. Clinical anesthesia. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. Clinical Review: Level 1, Grade A.

    Google Scholar 

  53. Miyauchi A, Inoue H, Tomoda C, Fukushima M, Kihara M, Higashiyama T, et al. Improvement in phonation after reconstruction of the recurrent laryngeal nerve in patients with thyroid cancer invading the nerve. Surgery. 2009;146:1056–62. doi:10.1016/j.surg.2009.09.018. Clinical Investigation: Level 2, Grade B.

    Article  PubMed  Google Scholar 

  54. Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41. Population/Observational Study: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  55. Sadler C, Gow KW, Beierle EA, Doski JJ, Langer M, Nuchtern JG, et al. Parathyroid carcinoma in more than 1,000 patients: a population-level analysis. Surgery. 2014;156:1622–9. doi:10.1016/j.surg.2014.08.069. Population/Observational Study: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  56. Genden EM. Parathyroid carcinoma. Oper Tech Otolaryngol Head Neck Surg. 2009;20:79–81. Clinical Review: Level 3, Grade A.

    Article  Google Scholar 

  57. Kauffmann RM, Juhlin CC, Fohn LE, Broome JT, Phay JE. Parathyroid carcinoma arising from four-gland hyperplasia. Endocr Pract. 2011;17:e37–42. doi:10.4158/EP10211.CR. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  58. Rathi MS, Ajjan R, Orme SM. A case of parathyroid carcinoma with severe hungry bone syndrome and review of literature. Exp Clin Endocrinol Diabetes. 2008;116:487–90. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  59. Te LI, Sheu WHH, Tu S-T, Kuo S-W, Pei D. Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. J Bone Miner Metab. 2006;24:255–8. Population/Observational Study: Level 4.

    Article  Google Scholar 

  60. Wang TS, Ostrower ST, Heller KS. Persistently elevated parathyroid hormone levels after parathyroid surgery. Surgery. 2005;138:1130–5. Population/Observational Study: Level 3, Grade A.

    Article  PubMed  Google Scholar 

  61. Palmieri-Sevier A, Palmieri GM, Baumgartner CJ, Britt LG. Case report: long-term remission of parathyroid cancer: possible relation to vitamin D and calcitriol therapy. Am J Med Sci. 1993;306:309–12. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  62. Munson ND, Foote RL, Northcutt RC, Tiegs RD, Fitzpatrick LA, Grant CS, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer. 2003;98:2378–84. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  63. Calandra DB, Chejfec G, Foy BK, Lawrence AM, Paloyan E. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery. 1984;96:1132–7. Population/Observational Study: Level 4.

    CAS  PubMed  Google Scholar 

  64. Bukowski RM, Sheeler L, Cunningham J, Esselstyn C. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med. 1984;144:399–400. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  65. Chahinian AP, Holland JF, Nieburgs HE, Marinescu A, Geller SA, Kirschner PA. Metastatic nonfunctioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. Am J Med Sci. 1981;282:80–4. Population/Observational Study: Level 4.

    Article  CAS  PubMed  Google Scholar 

  66. Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs. 2014;23:295–304. doi:10.1517/13543784.2014.867017. Basic Science Review: Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  67. Falchetti A, Becherini L, Martineti V, Morelli A, Benvenuti S, Picariello L, et al. Telomerase repeat amplification protocol (TRAP): a new molecular marker for parathyroid carcinoma. Biochem Biophys Res Commun. 1999;265:252–5. Basic Science: Level 1; Grade B.

    Article  CAS  PubMed  Google Scholar 

  68. Falchetti A, Franchi A, Bordi C, Mavilia C, Masi L, Cioppi F, et al. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res. 2005;20:410–8. Basic Science: Level 1; Grade B.

    Article  CAS  PubMed  Google Scholar 

  69. Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J, et al. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol. 2000;142(3):300–6. Clinical Investigation: Level 4.

    Article  CAS  PubMed  Google Scholar 

  70. Givi B, Shah JP. Parathyroid Carcinoma. Clin Oncol. 2010 Aug;22(6):498–507. Clinical Review: Level 3, Grade A.

    Google Scholar 

  71. Placzkowski K, Christian R, Chen H. Radioguided parathyroidectomy for recurrent parathyroid cancer. Clin Nucl Med. 2007;32:358–60. Population/Observational Study: Level 4.

    Article  PubMed  Google Scholar 

  72. Jo JH, Chung TM, Youn H, Yoo JY. Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis. Nat Commun. 2014;5:5433. doi:10.1038/ncomms6433. Basic Science: Level 1; Grade A.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, Stony Brook University School of Medicine, HSC T19-068, Stony Brook, NY, 11794-8191, USA

    Lukasz Czerwonka M.D.

  2. Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Hospital, University of Toronto, Mount Sinai Hospital, 600 University Avenue, Suite 401, Toronto, ON, Canada, M5G 1X5

    Nidal Muhanna M.D., Ph.D. & Jeremy Freeman M.D.

Authors
  1. Lukasz Czerwonka M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nidal Muhanna M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeremy Freeman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lukasz Czerwonka M.D. .

Editor information

Editors and Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    Brendan C. Stack, Jr.

  2. Department of Geniatrics and Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    Donald L. Bodenner

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Czerwonka, L., Muhanna, N., Freeman, J. (2017). Parathyroid Carcinoma. In: Stack, Jr., B., Bodenner, D. (eds) Medical and Surgical Treatment of Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26794-4_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26794-4_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26792-0

  • Online ISBN: 978-3-319-26794-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation